The prospective, non-interventional, pharmaco-vigilant study of antibiotic treatment of pediatric patients in pediatric intensive care unit and in-patient wards suffering from sepsis in a tertiary care hospital

Subhradipta Bhattacharyya1*, Manjushree Mohanty2

ABSTRACT

Background: Sepsis with septic shock has remained a dreadful disease inspite of early intervention mostly due to lack of sensitivity to first line antibiotics. This observational study was conducted to evaluate the utilization of antimicrobials and sensitivity-resistance pattern in paediatric patients suffering from sepsis due to various causes.

Methods: A prospective, non-interventional, pharmaco-vigilant study. 38 patients suffering from sepsis admitted in paediatric ward and PICU from September 2012 to February 2014 were evaluated. The research protocol was approved by Institutional Ethical Committee, KIMS. Data were collected from case sheets of patients from the ward as well as Medical Record and Data section. Average of Data on a continuous scale was expressed as a mean along with standard deviation, Categorical data was expressed as percentage. Comparative statistical analysis was done by using student’s t-test in respect of data measured on a continuous scale. All differences with P value below 0.05 were labelled as statistically significant.

Results: Total 38 patients were admitted with provisional diagnosis of sepsis. 52.5% patients were suffering from ≥2 diseases while pneumonia (64%) and meningitis (22%) were observed to cause sepsis. 10(27%) patients presented with septic shock while 39.3% patients having single organ failure and 10.4% patients having multiple organ failure. inj Dopamine (33%) and inj Dobutamine 11% were used and ventillator was used in 1 patient. Most of the patients received multiple antibiotics in I.V. route, 30 (79%) patients received ≥3 antibiotics. Linezolid+ piperacillin+ tazo + aminoglycoside + 4th drug combination was observed to be used in 34% patients while Linezolid+ 3rd gen. cephalosporin+ aminoglycoside+ 4th drug combination was used in 21% patients. Cephlosporin was most frequently withdrawn antibiotic (47 % of use). High resistance was observed for both gram +ve and gram -ve bacteria against cephlosporin.

Conclusions: Anti-MRSA agents (Linezolid) and anti-MDR GNB agent (Meropenem) significantly used to control the severe sepsis in conjunction to Piperacilin/ ceftrixone + amikacin.

Keywords: Antibiotic resistance, Combination of antibiotic, Sepsis, Septic shock resistance against commonly used antibiotics has made the situation worse.

INTRODUCTION

Sepsis is one of the leading cause of mortality and morbidity of pediatric population.1 Sepsis causes significant morbidity and mortality in children. Growing
Sepsis can be originated from various types of infection like bacterial, viral or fungal though no specific site of infection is found in most of the patients suffering from bacteremia or septicaemia.2

However, certain diseases or disease like states like pneumonia, meningitis, peritonitis, UTI etc if inadequately treated produce sepsis.3 In significant number of patients more than one diseases co-exist (e.g., pneumonia with meningitis) in a patient. Single or Multiple organ-system failure sometimes observed in patients of severe sepsis with shock. Despite early hospitalisation with prompt antibiotic administration, high mortality rate is observed.

Ever-increasing resistance against commonly used antibiotics is responsible for treatment failure in most of the cases.

In this present work, it was tried to evaluate the patients from one month to 15 years of age admitted in PICU and Pediatric ward over a period of 18 months. The antibiotic utilization pattern was evaluated along with sensitivity-resistance observed to antibiotics against isolated bacteria.

The observational study was conducted to evaluate the utilization of antimicrobials and sensitivity-resistance pattern in pediatric patients suffering from sepsis due to various causes.

Plan of the study

From September 2012 to February 2014 patients admitted in pediatric ward and PICU with provisional diagnosis of SEPSIS or BACTEREMIA were evaluated.

The present study is a non-interventional, uncontrolled, open chart, pharmaco-epidemiological and pharmacovigilant study. The research protocol was approved by Institutional Ethical Committee, KIMS.

METHODS

Within the study period from September 2012 to February 2014 about 70 patients were admitted in PICU and ward with proven or suspicion of sepsis of various infectious origin. Out of these patients, 38 patients have been evaluated. Data were collected from case sheets of patients from the ward as well as Medical Record and Data section of the Indoor patients receiving antibiotics along with supportive medications with provisional or confirmed BACTEREMIA OR SEPSIS.

Inclusion criteria

- Patients receiving antibiotics along with supportive medications with provisional or confirmed diagnosis of sepsis suffering from various infections like pneumonia, meningitis etc.
- Patients with confirmed diagnosis of sepsis who were discharged within one or two days, were excluded from the study.

Exclusion criteria

- Outdoor patients were excluded.
- Patients with severe renal impairment or hepatic failure were excluded from study sample.
- Patients who died were excluded from this study.

Study of the drug utilization pattern

Patients admitted in pediatric department were examined and data were collected according to pre-structured proforma. The following data were collected:

Demographic profile

This includes name, age, sex, body weight of the patients. These would help to illustrate the prevalence of a particular disease on different age or weight groups. As for example, Prevalence of sepsis, pneumonia or meningitis is significantly higher in 1m-1 yr age group (Figure 1).

Clinical presentation

This consists of history, brief clinical description, duration of illness, associated complaints, antibiotics taken elsewhere before admission in KIMS, previous illness or relevant family history etc.

General and systemic examination

It includes recording of heart rate, BP, anemia, jaundice and edema and weight. Weight of the patient was required for the dosage calculation.

Laboratory routine and specific investigation

- Laboratory investigations like TLC, DLC, Hb%, reticulocyte count, platelet count, MP, LFT, serum urea, creatinine, uric acid etc. were done routinely.

Blood c/s, Urine c/s, sputum c/s etc. were done whenever required.4

- ABG (arterial blood gas analysis) were done in patients of sepsis from pneumonia with respiratory failure routinely.
- CSF gram stain, C/S and cytology were done after LP routinely in Meningitis patients. CSF for viral marker or LAT (latex agglutination Test) to detect bacterial antigen were done in significant number of patients.
- Pleural fluid cytology or biochemical tests were done in patients of Pneumonia with pleural effusion.
- CRP, ALK-P, PT, serum electrolytes etc were done in sepsis patients.
Other investigations

- CXR are done routinely in Pneumonia or LRTI patients and repeated during the course of treatment.
- CT-thorax, USG chest were done in complicated pneumonia patients to detect pleural effusion or pneumothorax.
- EEG were done when seizure develop in meningitis or sepsis patients.
- Fundoscopy was done before LP in meningitis patients to detect papilloedema due to increased ICP.
- In meningitis patients Audiometry in most of the patients and BERA (Brain-stem Evoked Auditory Response) in a few cases were done to detect sensorineural hearing impairment at the time of discharge from hospital.

Drug utilization pattern

Data about the drugs prescribed was collected, mostly the antibiotics and antimicrobials. The route of administration, the dose, the frequency of dosing and the duration etc were noted.

Efficacy assessment of drugs

Primary efficacy parameters

- The clinical status of the patients was evaluated at frequent interval, from admission to discharge. The clinical improvement or deterioration was assessed in terms of various signs and symptoms, like improvement of shock and acidosis, improvement in GCS score, remission of fever, normalization of respiratory rate and pulse rate, subsidence of neck rigidity in meningitis, improvement of PAO2/FiO2 in ventilated patients of sepsis and pneumonia etc.
- Clinical improvement is considered as the major determining factor to evaluate the efficacy of an antimicrobial along with the safety.
- Severe sepsis patients often develop septic shock with or without single or multiple organ failure. Cardiovascular failure or dysfunction, respiratory dysfunction, hematologic dysfunction, neurological dysfunction or hepatic dysfunction are developed either alone or two/more than two organ-system at a time. The data regarding organ failure or septic shock were recorded from clinical notes.

Secondary efficacy parameters

Laboratory investigations

- Normalization of blood count (TLC, DLC, platelet count), Hb%, BUN, serum electrolytes, CRP, Alk-P etc.
- CSF sterilization and normalization of cytology in meningitis, eradication of bacteria from blood c/s or urine c/s in sepsis, sterilization of pleural fluid or sputum in LRTI or pneumonia etc.

Radiological assessment

Resolution of infiltration in CXR etc were noted in Pneumonia or LRTI, normalization of findings in CT/MRI in meningitis etc.

Adverse drug reaction monitoring.

Statistical analysis

Means of data on a continuous scale was expressed along with standard deviation /Error (Mean +/- SE). Comparative statistical analysis of two means was done by using Student’s t-test. For qualitative data, Chi square test was applied for comparisons of two means. All differences with P value below 0.05 were labelled as statistically significant.

RESULTS

Patient particulars

Among the 38 patients there were 25 male patients and 13 female patients.

Average age of the patients = 7.5±0.75 (SE) yr.

Average body weight = 23.58±2.17 (SE)Kg.

Average days of hospitalization = 14.4±1.17 (SE) days.

Age distribution of PICU patients

- There were 18.4% of total patients are within the age group of 1m-1yr. 10% of total patients are within the age group of 1yr-5yr and 29% patients are within the age group of 5-10yr. 40% patients are within the age group of 10yr-15yr (Figure 1).
- There is significantly higher percentage of patient density (year wise) in the age group of 1m-1yr (Chi-square applied, p <0.05).

![Figure 1: Age distribution of sepsis patients in PICU.](image-url)
Diseases associated with sepsis

Among the 38 patients evaluated, 10 (27%) patients presented with septic shock.

- It was found that 39.3% have failure of one organ, 10.4% patients have multi-organ failure. However, 50% patients did not develop any organ failure.
- Pneumonia or LRTI (64%) has been found to be most frequent disease to cause bacteremia or septicemia. In considerable number of patients pneumonia was co-existed with meningitis or UTI or bacillary dysentery (Figure 2).
- Meningitis (22%) alone or co-existing with pneumonia or UTI etc. has been found to be second most frequent cause to develop septicemia.10
- In significant number of patients (2.5%) viral or fungal infection had contributed to complicate the existing illness.
- In 52.5% patients two or more than two diseases (e.g.; pneumonia with meningitis with/without age) were co-existing.

Supportive treatments

Ionotropes

Septic shock was initially treated with iv fluids. Inj dopamine 5-10µg/kg/min was most commonly used ionotropes. Inj dopamine was used in 33% cases. Inj dobutamine (11%) was added in a few cases.

- Anticonvulsants: Sepsis patients often present with seizure and febrile convolution. Anti-epileptic drugs were used in 5.4% cases.
- Steroids: Inj dexamethasone was used 11% patients.
- Inj calcium-gluconate: Inj Ca-gluconate was used in 8.3% cases.
- Ventilator: In 1 patient ventilator was used.

Figure 2: Diseases contributing sepsis.

Figure 3: Different patients to receive multiple drugs.

As sepsis is an emergency condition most of the patients were immediately treated with combination of antibiotics in intravenous route along with supportive measures.11-13

- On an evaluation of empirical therapy, treatment was started with one drug regimen in 5 (13.2%) though Out of 5 only two patients completed their treatment successfully with single antibiotic.
- In 21 (55%) patients treatment were started with two antibiotics regimen. Only 6 out of 21 patients completed their treatment with having two drugs and in 15 patients ≥1 drugs were added.
- In 11 (29%) patients treatment were started with three drug regimen, only in 1 or 2 patients there was alteration/addition.
- There were 12 (31.6%) patients were found to have three drugs; 30 (79%) patients received three or more than three antibiotics during their illness whereas 18 (47.4%) patients received ≥ four drugs (Figure 3).
- In 5 (13.1%) patients treatment was started with one I.V. antibiotic however in three of them one or more antibiotics were added.
- In 12 (31.5%) patients either one or more antibiotics were replaced by other after the empirical regimen was started (e.g., Inj Linezolid was added or Inj Ceftriaxone was replaced by Inj Piperacillin, etc.).

Different combinations of antibiotics used

Used Drug combinations can be enumerated as follows:

- Linezolid + cefotaxim/ ceftriaxone + amikacin/gentamicin ≥4th drug= 21% patients
- Linezolid+ piperacillin + amikacin/gentamicin≥4th drug= 34%
- Carbapenem+ beta lactam + 3rd drug=10.5%
- Betalactam + aminoglycoside+ 3rd drug=18%
- Piperacillin+βl + aminoglycoside= 8.3%
- Cephalosporin+βl + aminoglycoside= 5.5%
- 3rd drug= tab cefuroxime/ tab ofloxacin/ tab azithro; 4th drug= antifungal/ anti malarial/ ATT
• There is 79% of patients received three or more than three drugs.
• Among them 21% received linezolid + cephalosporin+ aminoglycoside ±4th drug combination. 34% patients received linezolid+ piperacillin+ aminoglycoside+ 4th drug combination. 10.5% patients received carbapenem+ β-lactam + 3rd drug combination and 18.4% patients received β-lactam + aminoglycoside + 3rd drug combination (Figure 4).
• In 11 (28.9%) patients the existing empirical regimen was totally replaced by new drug regimen (e.g., Combination of Inj Pipzo and Inj Amikacin were replaced by Inj Linezolid and Inj Meropenem).

Duration of use

On average the different drugs were used are as following: Linezolid (10 days), Imipenem (9 days), Piperacillin-tazo (9 days), Cephalosporin (8 days), Amoxi-clav (7 days), Aminoglycoside (7 days) and Macrolide (3 days).

Individual antibiotics

• Aminoglycoside (22.4% of total antibiotic use) and Cephalosporin (18%) were two most frequently used drugs followed by Piperacillin+tazobactum (11.2%), Quinolone (7.8%), Amoxi-clav (5%) and Macrolide (3.9%).

Use of cephalosporin

• Ceftriaxone±β-LI was the most frequently used cephalosporin (87%) (Figure 5).
• Use of cephalosporin was found to be limited within second and third generation. Fourth generation cephalosporin like Cefepime or Cefpirome were not used.
• Inj ceftriaxone±sulbactum was used in dose of 50mg/kg I.V B.D.

• Inj cefoperazone ±tazobactum was used in a dose of 50 mg/kg I.V B.D for moderate infection. For severe infection the dose was found to be 110 mg/kg I.V B.D.

Use of quinolone (7.8%)

Ofloxacin (70%) and Ciprofloxacin (30%) were the most frequently used quinolones.

Use of macrolide (3.9%)

Azithromycin (87.5%) and Clarithromycin (12.5%) were mostly used. Azithromycin was used orally in a dose of 11.4 mg/kg OD. Clarithromycin was used orally in a dose of 9.3 mg/kg BD.

Use of penicillin

• Piperacillin+βLI (57%) was the most frequently used Penicillin followed by Amoxicillin+cloxacillin (27%) and Amoxicillin+βLI.
• Piperacillin was used in the dose range of 75-120mg/kg I.V TDS.
• Inj Ampicillin/amoxicillin + cloxacillin was used 40mg/kg/dose I.V QDS/TDS.
• In oral form Amoxi+ clav or Amoxicillin+ cloxacillin was used 20mg/kg/dose TDS.

Use of aminoglycosides (22.4%)

• Amikacin (82.5%) was most commonly used followed by Gentamicin (7.5%) and Netilmicin (10%).
• Inj Amikacin was used in the dose range of 7.5-10mg/kg I.V. BD. Inj Netilmicin was used 16mg/kg I.V B.D. Inj Gentamicin was used 2.2mg/kg I.V B.D.

Use of anti-MRSA and carbapenem

• Linezolid was given to total 21 patients. Among them in 5 patients it was given empirically at the beginning
and in 16 patients it was added later when gram positive cocci like staph. hemolyticus were isolated (Figure 6).
- Inj Linezolid was used in a dose of 10 mg/kg/dose I.V TDS/B.D.
- Once the patient was stabilized, oral formulations (tab/syrup) were used instead of I.V. in about 15 patients.
- In one patient Inj Linezolid was withdrawn due to thrombocytopenia.
- Inj Vancomycin was used in a dose of 10 mg/kg/dose I.V. TDS/QDS in 2 patients.
- Meropenem was used in 7 patients. In 5 cases it was added later on. The dose was 20 mg/kg I.V. TDS or 50mg/kg I.V BD.
- In four patients (10.5%) both Linezolid and Meropenem were used. Among them in 2 patients both the drugs were started from beginning.

Antifungals were used in 4% patients.

**DISCUSSION**

**Alteration/addition or withdrawal of antibiotics**

![Figure 6: Use of linezolid and carbapenem.](image)

- Among the first line antibiotics aminoglycoside was used in 26 (68%) patients, cephalosporin±βLI was used in 26 (68%) patients, piperacillin±βLI in 12 (31.6%) and Amoxi-clav in 8 (21%) patients.
- Cephalosporins were withdrawn in 11 patients (42.3% withdrawal), aminoglycoside in 3 patients (11.5% withdrawal), piperacillin±βLI in 2 patients (16.7% withdrawal) and Amoxi-clav in 2 patients (25% withdrawal). Meropenem was continued in all the given patients (Figure 7).
- On applying chi square test significant variation in percentage of antibiotic withdrawal (p<0.001) was observed which corroborated the findings in the sensitivity-resistance pattern found in the isolated bacteria.
- Among the second line drugs linezolid was used in 21 (55%) patients, meropenem 7 (18.4%), quinolone 7 (18.4%), Macrolide 4 (10.4%) and vancomycin 2 (5.3%) patients (Figure 8).
- Linezolid was withdrawn in 2 patients, vancomycin in 1 patient, quinolone in 2 patients.

![Figure 7: Use and withdrawal of antibiotics.](image)

- When no bacteria was found but severity of infection was not decreased, inj linezolid/vancomycin for gram positive coverage and inj piperacillin /meropenem for gram negative coverage were administered simultaneously.
- In 4 patients Linezolid and Meropenem both were used.
- Isolated gram +ve bacteria had shown high resistance against commonly used antibiotics.
- Poor sensitivity was observed for 3rd generation cephalosporin±βLI against gram positive (5.5%) and gram -ve (23.5%).
- Linezolid and vancomycin had shown 100% sensitivity to gram +ve bacteria.
- Effective sensitivity against gram -ve observed in carbapenem (72%), aminoglycoside (64.7%), piperacillin±βLI (57%) and Quinolone (58%) (Figure 9).

![Figure 8: Use and withdrawal of anti-MRSA/ carbapenem.](image)
Figure 9: Sensitivity observed in isolated bacteria.

Complications in sepsis patients in PICU and ward

- The patients admitted in ward or PICU with provisional diagnosis of sepsis often present with fever or hypothermia, altered mental status, features of septic shock like increased CRT, non-measurable BP or non-palpable pulses etc.
- Among the 36 patients evaluated, 10 (27%) patients presented with septic shock.6,7

Severity of sepsis according to diseases

It was observed that severity of sepsis was varied according to diseases of origin, however in most of the cases two or more than two diseases were (e.g., pneumonia with tuberculosis or meningitis with pneumonia etc) present in a patient. To receive more than three antibiotics and mean duration of hospitalisation were considered the parameters of severity of sepsis. The patients can be categorised according to diseases of origin in following groups:

- Sepsis predominantly originating from Pneumonia: 14 (87.5%) patients received ≥3 antibiotics, 9 (56%) patients to receive ≥4 antibiotics and mean duration of hospitalization was 12.5±5.34 days (Figure 10).
- Sepsis predominantly originated from Tuberculosis: 4 (100%) patients received ≥3 or 4 antibiotics (besides ATT) and mean duration of hospitalization was 28±5.83 days.
- Sepsis predominantly originated from Meningitis: 2 (33%) patients received ≥3 or 4 antibiotics and mean duration of hospitalization was 9±3.11 days.
- Sepsis with undiagnosed cause: 2 (50%) patients received ≥3 antibiotics, 1(25%) patients to receive ≥4 antibiotics, and mean duration of hospitalization was 10±3.55 days.
- Sepsis from viral/bacterial/protozoal infection: 7 (100%) patients received ≥3 antibiotics, 4 (57%) patients to receive ≥4 antibiotics and mean duration of hospitalization was 17±7.61 days.

However, since the severity of sepsis among 20 patients was very high, four or more than four antibiotics were administered during their treatment period. It was found that 100% of patients of sepsis originating from Pulmonary tuberculosis, 56% patients with pneumonia and 57% patients of viral/bacterial/protozoal infection required ≥4 antibiotics (Figure 11).

Applying chi-square test it was found p<0.001 i.e. the variation of severity of sepsis among different groups were due to type and severity of diseases/infections not by chance.

Patients with severe or very severe sepsis were deliberately included in the study that masks the actual scenario of sepsis in PICU and pediatric wards. For categorization of sepsis patients into moderate/severe or very severe, clinical notes from the case sheets were entirely followed.

Figure 10: Number of patients (in different diseases) to receive ≥3 antibiotics and mean duration of hospitalisation (days).

Figure 11: Percentage of patients of different diseases to receive ≥4 antibiotics.

No sepsis severity scale like, The Pediatric Logistic Organ Dysfunction (PELOD) score or The Pediatric multiple
organ dysfunction score (P MODS) were not applied. Expired patients were excluded from the study. Mortality rate was not evaluated for determining the efficacy of antibiotics.

CONCLUSION

Poor sensitivity was observed for 3rd generation cephalosporin±βLI against gram positive (5.5%) and gram -ve (23.5%). Effective sensitivity against gram -ve observed in carbapenem (72%), aminoglycoside (64.7%), piperacillin±βLI (57%) and Quinolone (58%). Linezolid and vancomycin had shown 100% sensitivity to gram +ve bacteria. Therefore, Anti-MRSA agents (Linezolid) and anti-MDR GNB agent (Meropenem) were used a lot confidently by the treating team to control the severe sepsis in conjunction with Piperacillin/ ceftriaxone + amikacin. 20 (52.6%) patients with very severe sepsis were administered four or more than four antibiotics in combination which immensely improved the survival of the patients.

ACKNOWLEDGEMENTS

Authors are Grateful to Department of Microbiology and Dr. A K Mohanty (Professor and HOD Department of Pediatrics) KIMS, Bhubaneswar, Orissa.

They are also grateful to Dr T.K. Bhattacharyya, Professor, Department of Pharmacology, MGM Medical College, Kishanganj, Bihar.

Funding: No funding sources
Conflict of interest: None declared
Ethical approval: The study was approved by the Institutional Ethics Committee of KIMS, Bhubaneswar, Orissa, India

REFERENCES
